Literature DB >> 28959043

Inflammation in gout: mechanisms and therapeutic targets.

Alexander K So1, Fabio Martinon2.   

Abstract

The acute symptoms of gout are triggered by the inflammatory response to monosodium urate crystals, mediated principally by macrophages and neutrophils. Innate immune pathways are of key importance in the pathogenesis of gout, in particular the activation of the NLRP3 inflammasome, which leads to the release of IL-1β and other pro-inflammatory cytokines. The orchestration of this pro-inflammatory cascade involves multiple intracellular and extracellular receptors and enzymes interacting with environmental influences that modulate the inflammatory state. Furthermore, the resolution of inflammation in gout is becoming better understood. This Review highlights recent advances in our understanding of both positive and negative regulatory pathways, as well as the genetic and environmental factors that modulate the inflammatory response. Some of these pathways can be manipulated and present novel therapeutic opportunities for the treatment of acute gout attacks.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28959043     DOI: 10.1038/nrrheum.2017.155

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  107 in total

1.  Multimodal Enzyme Delivery and Therapy Enabled by Cell Membrane-Coated Metal-Organic Framework Nanoparticles.

Authors:  Jia Zhuang; Yaou Duan; Qiangzhe Zhang; Weiwei Gao; Shulin Li; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Lett       Date:  2020-05-04       Impact factor: 11.189

Review 2.  Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.

Authors:  Holly Anderton; Ian P Wicks; John Silke
Journal:  Nat Rev Rheumatol       Date:  2020-07-08       Impact factor: 20.543

3.  β-carotene blocks the inflammasome.

Authors:  Joanna Clarke
Journal:  Nat Rev Rheumatol       Date:  2020-05       Impact factor: 20.543

4.  The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.

Authors:  Maryam Rashidi; Daniel S Simpson; Anne Hempel; Daniel Frank; Emma Petrie; Angelina Vince; Rebecca Feltham; Jane Murphy; Simon M Chatfield; Guy S Salvesen; James M Murphy; Ian P Wicks; James E Vince
Journal:  J Immunol       Date:  2019-06-17       Impact factor: 5.422

Review 5.  Charcot-Leyden Crystals in Eosinophilic Inflammation: Active Cytolysis Leads to Crystal Formation.

Authors:  Shigeharu Ueki; Yui Miyabe; Yohei Yamamoto; Mineyo Fukuchi; Makoto Hirokawa; Lisa A Spencer; Peter F Weller
Journal:  Curr Allergy Asthma Rep       Date:  2019-06-15       Impact factor: 4.806

6.  Wear Particle-induced Priming of the NLRP3 Inflammasome Depends on Adherent Pathogen-associated Molecular Patterns and Their Cognate Toll-like Receptors: An In Vitro Study.

Authors:  Givenchy W Manzano; Brian P Fort; George R Dubyak; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

7.  Gout in males: a possible role for COMT hypomethylation.

Authors:  Xiuru Ying; Yanfei Chen; Zhonghua Zheng; Shiwei Duan
Journal:  Clin Rheumatol       Date:  2019-06-04       Impact factor: 2.980

8.  Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation.

Authors:  Christopher J Hall; Leslie E Sanderson; Lisa M Lawrence; Bregina Pool; Maarten van der Kroef; Elina Ashimbayeva; Denver Britto; Jacquie L Harper; Graham J Lieschke; Jonathan W Astin; Kathryn E Crosier; Nicola Dalbeth; Philip S Crosier
Journal:  J Clin Invest       Date:  2018-03-26       Impact factor: 14.808

Review 9.  Neutrophils as emerging therapeutic targets.

Authors:  Tamás Németh; Markus Sperandio; Attila Mócsai
Journal:  Nat Rev Drug Discov       Date:  2020-01-22       Impact factor: 84.694

10.  The anti-inflammatory properties of HDLs are impaired in gout.

Authors:  Yuan Wang; Yan Wang; Xiaoxia Jia; Zongwei Wang; Xin Li; Lin Mu; Baoyu Zhang
Journal:  Clin Rheumatol       Date:  2020-09-01       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.